https://www.optimumcomms.com/wp-content/uploads/2026/03/Template_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-07-21 12:05:362026-07-21 12:05:36R1 Therapeutics announces commencement of global Phase 2b trial of AP306 for hyperphosphatemia in patients on dialysis
https://www.optimumcomms.com/wp-content/uploads/2026/03/Template_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-07-21 12:05:362026-07-21 12:05:36R1 Therapeutics announces commencement of global Phase 2b trial of AP306 for hyperphosphatemia in patients on dialysis
Poolbeg Pharma plc – Notice of Allowance received for POLB 001 Cancer Immunotherapy-induced CRS patent in Israel
Continued momentum in Poolbeg's global intellectual property…

Advanced Medical Solutions Group plc – Half Year 2026 Trading Update
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS),…

Mission Therapeutics strikes deal worth up to $292 million for Dimerix Ltd to develop Acute Kidney Injury asset MTX652, sharpens focus on its CNS pipeline
Mission Therapeutics has divested MTX652, a Phase 2-ready…

Simris Group AB Appoints ADC Expert Professor Andreas Pahl as Chief Executive Officer of its Subsidiary Simris Biologics GmbH
Simris Group AB (SIMRIS B) today announced the appointment…

Genopore appoints Rey Mali as Chief Executive Officer to accelerate growth of the pioneering protein identification company
San Francisco, California - Yavne, Israel – July 14th, 2026…

Nucleome Therapeutics strengthens global IP portfolio with US patent for core MCC Technology
Nucleome’s advance in precision and scale of 3D genomics has…

ViCentra Appoints Ian Wells as Chief Financial Officer and Adds Medtech Veteran Tom West to its Board
Ian Wells, former Global Chief Financial Officer of HOYA…

Poolbeg Pharma Plc – Placing to raise £3.5 million, Executive Chair Cathal Friel subscribes for £250,000
Poolbeg Pharma Plc (AIM: POLB), a clinical-stage biopharmaceutical…

Poolbeg Pharma plc – First Patient Dosed in the POLB 001 TOPICAL Clinical Trial
Interim data remains on track for summer 2026 and partnering…

Sofinnova Partners appoints David Evans as Partner
Sofinnova strengthens its growth strategy with a high-caliber…

No easy answers: European research consortia take on major challenges
Nine new Challenge Programme grants from the Novo Nordisk Foundation…

Hansa Biopharma to host Q2 2026 interim results conference call
Lund, Sweden, 8 July, 2026. Hansa Biopharma, “Hansa” (Nasdaq…

AMSilk and Ajinomoto Foods Europe Expand Partnership to Enable Industrial-Scale Production of Silk Proteins
Neuried/Nesle, 8 July 2026 - AMSilk, a global leader in biotech…

Xeltis makes first commercial implant of aXess™, its vascular access device for hemodialysis
Marks start of European commercial rollout of aXess™, bringing…

Sofinnova Partners announces Myricx Bio agrees to be acquired by Novartis
Sofinnova Partners co-led the seed investment in 2019 and…
We’d love to hear from you
For more information about Optimum Strategic Communications, please get in touch.
Optimum Strategic Communications’ specialist team has an in-depth understanding of how to communicate complex science to investors and corporate stakeholders. Optimum helps life science companies on their journey as they grow and has been trusted by hundreds of healthcare clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York